Skip to main content

Everotas 5 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTION

Everotas 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everotas 5mg is an immunosuppressive macrolide.

USED FOR

Breast cancer 
The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Everotas. Everotas 5mg is used in an advanced stage of breast cancer.

Neuroendocrine tumors 
Everotas 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer.

Renal cell cancer 
Patient treating with Everotas 5mg after the failure of treatment with Sunitinib or Sorafenib.
Everotas 5mg also used in the condition of; Heart, liver, kidney transplantation
Waldenström macroglobulinemia
Other carcinoid tumors.

MECHANISM OF ACTION

Everotas is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase.
Everotas bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex 1 (mTORC1) this leads to inhibition of mTOR kinase activity.
Everotas decreased the effect of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E binding protein (4E-BP1) which are essential for protein synthesis.

DOSAGE AND ADMINISTRATION

The recommended dose of the Tablet Everotas is 10mg should be taken as a single dose in all carcinogenic condition, except organ transplantation.
Organ transplant: 0.75mg orally twice daily.
Brain/intracranial tumor: 4.5mg/m2 orally once a day (for both pediatric and adult dose)
Hepatic impairment: dose reduced to 7.5mg once daily followed by 5mg as a single dose.
Everotas is in tablet form. It should be administered orally at the same time every day.
Everotas should be taken with or without food.
Everotas tablets should not crush or broken.

CONTRAINDICATION

Everotas 5mg is contraindicated to sirolimus and other rapamycin derivatives, to produce anaphylactic reactions.

PREGNANCY

Everotas 5mg should not use in pregnancy conditions and for breastfeeding mothers.
Pregnancy category: C
Everotas 5mg causes harm or any malformation in unborn babies.

STORAGE

Everotas 5mg should be stored in room temperature
Keep away from moisture, heat, and light

MISSED DOSE

In the case of the missed dose, patients must consult with medical practitioner and follow the instructions given by them.
On the other hand, the missed dose should be avoiding and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:
info@blueberrypharma.com

PHONE:
+91-97890 77748

VISIT US:
Labels:

Comments

Post a Comment

Popular posts from this blog

EVEROLIMUS TABLETS COST IN INDIA

EVEROLIMUS DESCRIPTION  Everolimus  belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor).  Everolimus  is an immunosuppressive macrolide. EVEROLIMUS USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with  Everolimus .  Everolimus  is used in the advanced stage of breast cancer. Neuroendocrine tumors  Everolimus involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer Patient treating with  Everolimus  after the failure of treatment with Sunitinib or Sorafenib.  Everolimus  also used in the condition of Heart, liver, kidney transplantation, Waldenstrom macroglobulinemia, Other carcinoid tumors Brand: Evertor Strength: 10mg Ingredient: Everolimus Company Name: Biocon Tab Count: 10 Tablets MECHANISM OF ACTION Everolimus  is the prohibition o
1 comment
Read more

Nivolumab (Opdivo & Opdyta) Injection Online | Blueberry pharmaceuticals

NIVOLUMAB Nivolumab belongs to a group of cancer drugs known as monoclonal antibodies. Nivolumab is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. Nivolumab is a prescription drug which is used under the supervision of a doctor INDICATION Nivolumab is indicated for the treatment of patients having Melanoma. Nivolumab is indicated for the treatment of patients having Non-Small Cell Lung Cancer. Nivolumab is indicated for the treatment of patients having Kidney (Renal Cell) Cancer. MECHANISM OF ACTION Nivolumab prohibits the molecule activity called PD-1, and it is a protein which prevents T cells from recognizing and attacking inflamed tissues and cancer cells. PD-1 can deceit the immune system into overlooking melanoma cells as normal cells. DOSAGE AND ADMINISTRATION Nivolumab recommended dosage for unresectable or metastatic melanoma : As a single
Post a Comment
Read more

Rapact 10 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTION Rapact 10mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Rapact 10mg is an immunosuppressive macrolide. USED FOR Breast cancer  Patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Rapact. Rapact 10mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Rapact 10mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  patient treating with Rapact 10mg after the failure of treatment with Sunitinib or Sorafenib. Rapact 10mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Rapact is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Rapact bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex
Post a Comment
Read more